We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other ...

Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and provided a disappointing guidance for 2025. On Feb. 4, Merck announced its ...

Imagine yourself as a passive income investor looking for a medical stock with significant share growth potential. Wall ...

Great investments are even better and more fruitful when you can buy them at a discount. Lots of investors enjoy keeping an ...

Adding Winrevair to standard pulmonary arterial hypertension (PAH) treatment is generally safe and effective, a pooled trial ...

Notably, Merck's Winrevair pulmonary arterial hypertension (PAH) medication is on track to be the company's next blockbuster drug, already delivering $419 million in sales in just the first two ...

In the third quarter, Merck reported a decline of 11% in Gardasil sales to $2.31 billion. The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated sales ...

Medicare Part D redesign is expected to hurt sales by approximately $400 million, primarily affecting Winrevair and oncology products, including Welireg, Lynparza and Lenvima. Merck expects top ...